Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7734847rdf:typepubmed:Citationlld:pubmed
pubmed-article:7734847lifeskim:mentionsumls-concept:C0330390lld:lifeskim
pubmed-article:7734847lifeskim:mentionsumls-concept:C0016964lld:lifeskim
pubmed-article:7734847lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:7734847lifeskim:mentionsumls-concept:C0702242lld:lifeskim
pubmed-article:7734847lifeskim:mentionsumls-concept:C0023276lld:lifeskim
pubmed-article:7734847lifeskim:mentionsumls-concept:C1880022lld:lifeskim
pubmed-article:7734847lifeskim:mentionsumls-concept:C0065051lld:lifeskim
pubmed-article:7734847pubmed:issue6lld:pubmed
pubmed-article:7734847pubmed:dateCreated1995-6-8lld:pubmed
pubmed-article:7734847pubmed:abstractTextLipophosphoglycan (LPG) is the major cell surface molecule of promastigotes of all Leishmania species. It is comprised of three domains: a conserved GPI anchor linked to a repeating phosphorylated disaccharide (P2; PO4-6-Gal(beta 1-4)Man(alpha 1-) backbone variously substituted with galactose, glucose and arabinose residues in L.major and capped with a neutral oligosaccharide. Using a microsomal membrane preparation from L.major, we have been able to demonstrate that galactose from UDP-[14C]galactose can be transferred to an endogenous acceptor, characterized as LPG. An in vitro assay was established, based on anion-exchange HPLC, that concurrently identifies and quantitates the products of the galactosyltransferases. We show that the products formed are [14C]galactose-labelled P3 (PO4-6-[Gal(beta 1-3)]Gal(beta 1-4)Man(alpha 1-), P4b (PO4-6-[Gal(beta 1-3)Gal(beta 1-3)]Gal(beta 1-4)Man(alpha 1-) and P5b(PO4-6-[Gal(beta 1-3)Gal(beta 1-3)Gal(beta 1-3)]Gal(beta 1- 4)Man(alpha 1-). These are major galactosylated repeating units of the backbone of L.major LPG. The same products are also formed when LPG from L.donovani, which contains an unbranched backbone of P2 repeats, is used as an exogenous acceptor with L.major microsomal membranes and UDP-[14C]galactose. In addition, no formation of radioactive backbone repeats (P2) was detected in membrane incubations containing UDP-[14C]galactose with or without added unlabelled GDP-mannose, indicating that the addition of the (beta 1-3)-linked galactose branches is independent of the synthesis of the repeating disaccharide (P2) backbone. Preliminary kinetic analyses suggest that the addition of multiple (beta 1-3)-linked galactose residues may be catalysed by more than one (beta 1-3) galactosyltransferase. The (beta 1-3)galactosyltransferase(s) activity was not detected in microsomal membrane preparations from promastigotes of L.donovani.lld:pubmed
pubmed-article:7734847pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7734847pubmed:languageenglld:pubmed
pubmed-article:7734847pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7734847pubmed:citationSubsetIMlld:pubmed
pubmed-article:7734847pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7734847pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7734847pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7734847pubmed:statusMEDLINElld:pubmed
pubmed-article:7734847pubmed:monthDeclld:pubmed
pubmed-article:7734847pubmed:issn0959-6658lld:pubmed
pubmed-article:7734847pubmed:authorpubmed-author:HandmanEElld:pubmed
pubmed-article:7734847pubmed:authorpubmed-author:OIHHlld:pubmed
pubmed-article:7734847pubmed:authorpubmed-author:BacicAAlld:pubmed
pubmed-article:7734847pubmed:issnTypePrintlld:pubmed
pubmed-article:7734847pubmed:volume4lld:pubmed
pubmed-article:7734847pubmed:ownerNLMlld:pubmed
pubmed-article:7734847pubmed:authorsCompleteYlld:pubmed
pubmed-article:7734847pubmed:pagination845-53lld:pubmed
pubmed-article:7734847pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:7734847pubmed:meshHeadingpubmed-meshheading:7734847-...lld:pubmed
pubmed-article:7734847pubmed:meshHeadingpubmed-meshheading:7734847-...lld:pubmed
pubmed-article:7734847pubmed:meshHeadingpubmed-meshheading:7734847-...lld:pubmed
pubmed-article:7734847pubmed:meshHeadingpubmed-meshheading:7734847-...lld:pubmed
pubmed-article:7734847pubmed:meshHeadingpubmed-meshheading:7734847-...lld:pubmed
pubmed-article:7734847pubmed:meshHeadingpubmed-meshheading:7734847-...lld:pubmed
pubmed-article:7734847pubmed:meshHeadingpubmed-meshheading:7734847-...lld:pubmed
pubmed-article:7734847pubmed:meshHeadingpubmed-meshheading:7734847-...lld:pubmed
pubmed-article:7734847pubmed:meshHeadingpubmed-meshheading:7734847-...lld:pubmed
pubmed-article:7734847pubmed:meshHeadingpubmed-meshheading:7734847-...lld:pubmed
pubmed-article:7734847pubmed:meshHeadingpubmed-meshheading:7734847-...lld:pubmed
pubmed-article:7734847pubmed:year1994lld:pubmed
pubmed-article:7734847pubmed:articleTitleBiosynthesis of lipophosphoglycan from Leishmania major: characterization of (beta 1-3)-galactosyltransferase(s).lld:pubmed
pubmed-article:7734847pubmed:affiliationWalter and Eliza Hall Institute of Medical Research, Royal Melbourne Hospital, Victoria, Australia.lld:pubmed
pubmed-article:7734847pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7734847pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:7734847pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7734847lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7734847lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7734847lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7734847lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7734847lld:pubmed